Bcl-2 expression significantly correlates with thymidylate synthase expression in colorectal cancer patients
Authors:
- Riyad BendardafRBRiyad Bendardaf
- Raija RistämakiRRRaija Ristämaki
- Kari SyrjänenKSKari Syrjänen
- Seppo PyrhönenSPSeppo Pyrhönen
Open Access
- 1 January 2008
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (40) , 6218-6223
Abstract
AIM: To examine the expression of thymidylate synthase (TS) and oncoprotein Bcl-2 in advanced colorectal cancer (CRC) patients, and to determine their mutual relationship, association to therapeutic response and impact on disease outcome. METHODS: Tumor samples from 67 patients with CRC, who were treated at advanced stage with either irinotecan alone or in combination with 5-fluorouracil/leucovorin, were analyzed for expression of TS and Bcl-2 using immunohistochemistry. RESULTS: A significant linear correlation between lower expression levels of Bcl-2 and lower levels of TS expression was found (P = 0.033). Patients with high levels of both TS and Bcl-2 expression had a significantly longer disease-free survival (DFS) (42.6 mo vs 5.4 mo, n = 25) than those with low TS/Bcl-2 index (P = 0.001). Tumors with low levels of both TS and Bcl-2 were associated with a longer survival with metastasis (WMS) interval in the whole patients group (n = 67, P = 0.035). TS/Bcl-2 index was not significantly related to disease-specific survival. CONCLUSION: The present data suggest that CRC patients with low TS/Bcl-2 demonstrate a significantly shorter DFS and longer WMS.Keywords
This publication has 26 references indexed in Scilit:
- Thymidylate synthase expression levels: A prognostic and predictive role in advanced colorectal cancerOncology Reports, 2005
- Cancer incidence and mortality in Europe, 2004Annals of Oncology, 2005
- Apoptotic Index and bcl-2 Expression as Prognostic Factors in Colorectal CarcinomaOncology, 2003
- Thymidylate Synthase Expression in Hepatic Tumors Is a Predictor of Survival and Progression in Patients With Resectable Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancerAnnals of Oncology, 2002
- bcl‐2 protein expression is associated with better prognosis in colorectal cancerHistopathology, 1999
- A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significanceCancer, 1998
- Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trialEuropean Journal of Cancer, 1995
- Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)Nature, 1991
- Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 1990